The Oncology Institute (TOI)
Manages community cancer care with patient services, specialty pharmacy, and clinical trials.
BlackRock Inc. Buys Shares of 4,749,030 The Oncology Institute, Inc. $TOI
BlackRock Inc. purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ: TOI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,749,030 shares of the company's stock, valued at approximately $25,787,000. BlackRock Inc. owned approximately 4.80% of Oncology Institute
Oncology Institute Q2 Earnings Call Highlights
Oncology Institute NASDAQ: TOI reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology.
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 2026 financial results on Thursday, August 6, 2026, to be followed by a conference call the same day at 5:00 p.m.
Best Cheap Stocks Under $10 to Buy Now in July
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?
The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B.
Oncology Institute Q1 Earnings Call Highlights
Oncology Institute NASDAQ: TOI reported a strong start to 2026, with first-quarter revenue rising 41% year over year as the company expanded value-based care arrangements and posted record specialty pharmacy performance.
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue Estimates
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026.
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the first quarter ended March 31, 2026. Please note that all amounts referred to in this press release are in Euros unless otherwise stated.
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m.
Topicus.com Inc. Announces Release Date for First Quarter Results
TORONTO, April 15, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its first quarter results on May 5, 2026.
Jorey Chernett Purchases 20,000 Shares of Oncology Institute (NASDAQ:TOI) Stock
The Oncology Institute, Inc. (NASDAQ: TOI - Get Free Report) major shareholder Jorey Chernett acquired 20,000 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were bought at an average price of $3.10 per share, for a total transaction of $62,000.00. Following the completion of the transaction, the insider owned 10,499,358
Constellation Software Inc., Topicus.com Inc. and Lumine Group Inc. Announce Annual Meetings
TORONTO, April 10, 2026 (GLOBE NEWSWIRE) -- The Topicus.com Inc. (“Topicus”) (TSXV:TOI) annual general meeting of shareholders will be held on Friday, May 15, 2026 at 8:00 a.m. ET using a hybrid meeting format with proceedings conducted via live webcast and in person. The Lumine Group Inc. (“Lumine Group”) (TSXV:LMN) annual general meeting of shareholders will be held on Friday, May 15, 2026 at 8:15 a.m. ET using a hybrid meeting format with proceedings conducted via live webcast and in person. The Constellation Software Inc. (“Constellation” or “CSI”) (TSX:CSU) annual meeting of shareholders will be held on Friday, May 15, 2026 at 8:30 a.m. ET using a hybrid meeting format with proceedings conducted via live webcast and in person.
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025.